Sarilumab COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

March 28, 2020

Primary Completion Date

July 31, 2020

Study Completion Date

September 2, 2020

Conditions
Corona Virus Infection
Interventions
DRUG

Sarilumab SAR153191

Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion

DRUG

Placebo

Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion

Trial Locations (47)

1430

Investigational Site Number 0320001, Caba

20089

Investigational Site Number 3800006, Rozzano

20122

Investigational Site Number 3800005, Milan

20132

Investigational Site Number 3800001, Milan

20157

Investigational Site Number 3800002, Milan

28007

Investigational Site Number 7240002, Madrid

28034

Investigational Site Number 7240005, Madrid

28046

Investigational Site Number 7240001, Madrid

33076

Investigational Site Number 2500001, Bordeaux

41100

Investigational Site Number 3800003, Modena

43100

Investigational Site Number 3800004, Parma

44093

Investigational Site Number 2500002, Nantes

45147

Investigational Site Number 2760002, Essen

48149

Investigational Site Number 2760001, Münster

50937

Investigational Site Number 2760004, Cologne

52662

Investigational Site Number 3760001, Ramat Gan

67098

Investigational Site Number 2500003, Strasbourg

75877

Investigational Site Number 2500005, Paris

85925

Investigational Site Number 2500006, La Roche-sur-Yon

91120

Investigational Site Number 3760002, Jerusalem

92140

Investigational Site Number 2500007, Clamart

92151

Investigational Site Number 2500004, Suresnes

111539

Investigational Site Number 6430003, Moscow

123182

Investigational Site Number 6430002, Moscow

129301

Investigational Site Number 6430001, Moscow

3460001

Investigational Site Number 1520001, Talca

7747629

Investigational site number 3760003, Ashdod

80004005

Investigational Site Number 1520002, Santiago

C1180AAX

Investigational Site Number 0320003, Caba

C1426AAM

Investigational Site Number 0320004, Caba

90110-270

Investigational Site Number 0760003, Porto Alegre

15090-000

Investigational Site Number 0760004, São José do Rio Preto

01327-001

Investigational Site Number 0760001, São Paulo

04231-030

Investigational Site Number 0760002, São Paulo

04321-120

Investigational Site Number 0760005, São Paulo

H2X3E4

Investigational Site Number 1240001, Montreal

H4A 3J1

Investigational Site Number 1240005, Montreal

M4N3M5

Investigational Site Number 1240004, Toronto

M5G 2N2

Investigational Site Number 1240002, Toronto

V5Z 1M9

Investigational Site Number 1240003, Vancouver

750-0691

Investigational Site Number 1520003, Santiago

Unknown

Investigational Site Number 1520004, Santiago

Investigational Site Number 3920002, Fuchu-Shi

Investigational Site Number 3920003, Iruma-Gun

Investigational Site Number 3920001, Kamakura-Shi

08035

Investigational Site Number 7240003, Barcelona

08036

Investigational Site Number 7240004, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY